Jun 11, 2018 · 34m · 20vc
20VC: Why Process is Everything In Good Venture Firms, Why GPs Should Have More Empathy For LPs and Lessons from 32 Years In VC, Chairing Over 25 Boards with Peter Parker, Managing Partner @ Bioinnovation Capital
0:00 / 0:00
gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions
In this episode of The Twenty Minute VC, host Harry Stebbings interviews veteran investor Peter Parker, Managing Partner at BioInnovation Capital, who shares key insights from his 32-year career in venture capital. Parker discusses the evolution of life science investing, effective partnership governance, LP fundraising empathy, and strategic risk management in biotech.
How this conversation actually went
Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. Harry holds 30.1% of the talking time here. How this is scored →
Harry as informed peer 2.6 Guest teaching 4.0 Guest disagreement 1.1 Harry pushing back 1.4
speaking balance: gold is Harry, purple is the guest (3 minute bins)
Sharpest disagreement ▶ 24:33 Rejection of the 'aqua-hire' label in biotech
Peter directly counters Harry's premise that early biotech M&A is just a series of low-value aqua-hires, explaining that pharma acquirers buy early-stage technology to fill commercial drug pipelines.
Hardest push from Harry ▶ 10:23 Challenging unanimous consensus decision-makingHarry pushes back directly on Peter's unanimous partnership voting rule, questioning whether requiring consensus destroys the outlier returns central to venture capital.
Biggest teaching moment ▶ 24:33 Explaining the mechanics of modern biotech M&APeter educates Harry on how big pharma's reduction in internal research headcounts created a reliance on external R&D, enabling high-return Series A acquisitions.
Harry holds his own ▶ 26:03 Highlighting follow-on reserve traps in biotechHarry demonstrates keen domain knowledge of venture portfolio dynamics by challenging Peter on the risk of having to carry biotech companies longer when lifecycle follow-on capital is scarce.
the scores for every segment, with the reasoning behind each
| Chapter | Topic | Harry as informed peer | Guest teaching | Guest disagreement | Harry pushing back | Why |
|---|---|---|---|---|---|---|
| Peter Parker's Transition from R&D to Venture Capital | 1 | 3 | 1 | 0 | Harry takes a deferential approach, asking high-level setup questions about Peter's entrance into VC and the evolution of the industry over 30 years. Peter provides context on the shift from generalist firms to extreme specialization. | |
| Comparative Fund Founding Lessons and Operational Process | 2 | 4 | 1 | 0 | Harry relays a prompt from Peter's son Andrew about lessons learned between founding firm one and firm two. Peter explains how BioInnovation Capital adapted lean startup concepts to biotech via shared lab spaces like Lab Central. | |
| Partnership Decision-Making and Unanimity in Investment Choices | 4 | 3 | 1 | 4 | When Peter explains his firm's strict requirement for unanimous partnership decisions, Harry interjects with a sharp counterpoint asking if consensus kills outlier returns. Peter clarifies that they remain open to smaller initial checks to accommodate outlier opportunities. | |
| Refining the LP Pitch and Leveraging Experiential Diligence | 2 | 4 | 1 | 0 | Harry asks about Peter's recent fundraise and how his pitching style evolved over 30 years. Peter explains the power of concise 4-slide pitches and using physical lab visits as an effective diligence closer for LPs. | |
| Strategic Alignment Through Quantifiable Annual Board Goals | 3 | 5 | 1 | 1 | Harry asks about Peter's governance evolution after chairing over 25 boards. Peter outlines a strict methodology of requiring companies to set five quantifiable annual objectives to streamline board evaluations. | |
| Constructive Approaches to Executing Executive Leadership Changes | 3 | 5 | 2 | 1 | Harry explores the dynamics of replacing CEOs gently before transitioning to differences between tech and biotech VC. Peter explains that biotech faces scientific risk with guaranteed market demand, while expressing skepticism toward VC-created funds lacking true founders. | |
| Portfolio Risk Management and Strategic Acquisition Dynamics in Biotech | 5 | 6 | 2 | 5 | Harry pushes back on biotech venture models, citing common industry critiques regarding low-value early acquisitions and lifecycle follow-on funding traps. Peter corrects the premise by detailing big pharma's external R&D reliance and demonstrating how early asset acquisitions yield strong portfolio returns. | |
| Quick Fire Insights on Surfing, LP Anecdotes, and Graphware | 1 | 2 | 0 | 0 | In a lighthearted quickfire segment, Peter shares stories about reading surfing memoirs, a hilarious encounter with an intoxicated LP, and his recent investment in wearable sensor startup Graphware. |
Statements from this episode (20)
3M Post-It Note Was Invented to Communicate With CEO
“Three M is a great example of this, where the post-it note was famously invented by someone who just needed a way to communicate with the CEO on a piece of sticky paper.”
The VC Industry Had Only 200 Firms Worldwide in the Late 1980s
“There were probably, we thought, maybe 200 venture firms in the world, and in those days, the U.S. Was the predominant player in venture capital. Now, this is early stage venture capital. A lot of these were efforts that spun out of investment banks or other e…”
No VC Firms Called Themselves Life Sciences Funds in the Late 1980s
“So back in the late eighties, there were very few specialized firms at all. None that I knew of that would call themselves, for instance, life sciences firms.”
High-Performing VC Firms Rely on Detailed Systems and Process
“I think process is almost everything in good venture firms. If you get under the hood of any firm that you really respect, I think you'll find a very, very detailed process. Even though it looks chaotic, they have a pretty set system.”
Every Portfolio Company Inevitably Faces Major Trouble
“It's not a question of whether these companies are going to get into trouble. It's just a question of when.”
BioInnovation Capital Requires Unanimous Partner Consensus to Invest
“We passed on deals where one partner had just serious reservations and four would have voted for it. And that was true at Ampersand. It's true at Bioinnovation Capital as well.”
VCs Are Middlemen and the Cult of Personality Is Unwarranted
“My view of the world is we're middlemen. It's their capital, and we're finding great places to put it. That sounds pretty pedestrian. I really don't like the cult of Personality that sometimes accrues to very, very big names in the venture business. I'm not su…”
If You Cannot Pitch in Four Slides, You Haven't Mastered Your Story
“If you can't tell the story in four slides, you know, you just haven't really got your pitch down well”
BioInnovation Capital Converts 100% of LPs Who Visit Their Lab Space
“When we can get an LP there, meaning this may say the second meeting is at our shop, I think we've gotten a hundred percent of those people to invest in the funds.”
Startups Cannot Effectively Focus on More Than 10 Annual Objectives
“So beyond 10 objectives, we don't feel they can really be focusing on things that we think will change the outcome of the company.”
Failing Top Three Annual Objectives Indicates Serious Startup Problems
“Yeah, if companies aren't hitting their top two or three objectives, and if they're reasonable objectives, yeah, something's wrong.”
Peter Parker Has Replaced Approximately 15 CEOs Throughout His Career
“I mean, I've changed probably 15 CEOs in my life.”
CEO Goals Are Company Goals, Making Sustained Underperformance Impossible
“There's no difference between the CEO's goals and the company goals, and if they really are just lagging behind dramatically, then it's just not something you can sustain.”
No New Major Pharma Companies Will Be Built From Biotech VC
“There are very few, there won't be any new major pharmaceutical companies created out of biotech VC money anymore. Really all about creating companies that can exit to these people.”
VCs Should Not Invest in Their Own Internally Created Ideas
“I was sort of raised in the world that said, don't invest in your own ideas. Wait for the guy with passion to come in the front door and really sway you that this is an important idea.”
Pharma Internal Research Headcount Dropped 5-6% Annually Over the Past Decade
“If you look at the last 10 years, the research headcount in pharma has gone down by five or six percentage points per annum, so they're half as big internal research, but now what they've done is created external R&D groups, so they're out shopping, and we hav…”
BioInnovation Capital Targets Portfolio Exits Under $50M Total Funding
“So we like to say the companies have to be able to exit by the time fifty million dollars of venture money has gone in.”
BioInnovation Capital Targets Gains on Two-Thirds of Portfolio Companies
“I'd like to see a portfolio with two thirds of my companies being gains for us. And so not relying on the 50 to one winner to Drive the whole portfolio. I think that's just too hard to do.”
Investors Make Money in Winners, but Friends in Losers
“One that's kicking around in my head recently is, you know, back in September, Fred Wilson, in his blog, he quoted Brad Feld, who said that, you make money in winners, but you make friends in losers. And, you know, it's absolutely so true, and it's been very t…”